Skip to main content

Table 1 Patient’s characteristics and their correlations with STAT3 polymorphism genotypes

From: Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab

Clinical parameters No. Genotype p Clinical parameters No. Genotype p
   CC + GG CG     CC + GG CG  
Gender      IPI score     
Male 82 50 32 0.042 0-2 116 61 55 0.867
Female 84 38 46   3-5 50 27 23  
Age      Bulky mass     
≤60 106 59 47 0.364 ≥10 cm 33 19 14 0.557
>60 60 29 31   <10 cm 133 69 64  
B symptoms      Localized     
Positive 63 31 32 0.442 Yes 27 17 10 0.258
Negative 103 57 46   No 139 71 68  
LDH      Extra Nodal Site     
Positive 78 39 39 0.464 ≤1 123 64 59 0.669
Negative 88 49 39   >1 43 24 19  
β-2 MG      Incidence Site     
Positive 51 23 28 0.091 Lymph node 95 46 49 0.170
Negative 106 63 43   Extra lymph 71 42 29  
ESR      Ki-67     
Positive 77 36 41 0.132 ≤75 66 32 34 0.329
Negative 80 47 33   >75 85 48 37  
Stage      Subtype     
I-II 78 42 36 0.839 GCB 29 18 11 0.229
III-IV 88 46 42   Non-GCB 113 56 57